Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Diagnostic Aids for Detection and Diagnosis of Oral Cancer
Evaluation of Diagnostic Aids for Detection and Diagnosis of Oral Cancer
Status: Enrolling
Updated:  4/1/2016
Fanconi Anemia Research Fund (FARF)
mi
from
Eugene, OR
Diagnostic Aids for Detection and Diagnosis of Oral Cancer
Evaluation of Diagnostic Aids for Detection and Diagnosis of Oral Cancer
Status: Enrolling
Updated: 4/1/2016
Fanconi Anemia Research Fund (FARF)
mi
from
Eugene, OR
Click here to add this to my saved trials
Diagnostic Aids for Detection and Diagnosis of Oral Cancer
Evaluation of Diagnostic Aids for Detection and Diagnosis of Oral Cancer
Status: Enrolling
Updated:  4/1/2016
Good Neighbor Healthcare Center (GNHC)
mi
from
Houston, TX
Diagnostic Aids for Detection and Diagnosis of Oral Cancer
Evaluation of Diagnostic Aids for Detection and Diagnosis of Oral Cancer
Status: Enrolling
Updated: 4/1/2016
Good Neighbor Healthcare Center (GNHC)
mi
from
Houston, TX
Click here to add this to my saved trials
Diagnostic Aids for Detection and Diagnosis of Oral Cancer
Evaluation of Diagnostic Aids for Detection and Diagnosis of Oral Cancer
Status: Enrolling
Updated:  4/1/2016
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Diagnostic Aids for Detection and Diagnosis of Oral Cancer
Evaluation of Diagnostic Aids for Detection and Diagnosis of Oral Cancer
Status: Enrolling
Updated: 4/1/2016
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Dendritic Cell Vaccine Study (DC/PC3) for Prostate Cancer
A Phase I/II Study of Autologous Dendritic Cells Pulsed With Apoptotic Tumor Cells (DC/PC3) Administered Subcutaneously to Prostate Cancer Patients.
Status: Enrolling
Updated:  4/1/2016
Rockefeller University Hospital
mi
from
New York, NY
Dendritic Cell Vaccine Study (DC/PC3) for Prostate Cancer
A Phase I/II Study of Autologous Dendritic Cells Pulsed With Apoptotic Tumor Cells (DC/PC3) Administered Subcutaneously to Prostate Cancer Patients.
Status: Enrolling
Updated: 4/1/2016
Rockefeller University Hospital
mi
from
New York, NY
Click here to add this to my saved trials
HELOISE Study: A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer
Status: Enrolling
Updated:  4/2/2016
Clinical Research Facility
mi
from
La Jolla, CA
HELOISE Study: A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer
Status: Enrolling
Updated: 4/2/2016
Clinical Research Facility
mi
from
La Jolla, CA
Click here to add this to my saved trials
HELOISE Study: A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer
Status: Enrolling
Updated:  4/2/2016
Clinical Research Facility
mi
from
Los Angeles, CA
HELOISE Study: A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer
Status: Enrolling
Updated: 4/2/2016
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
HELOISE Study: A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer
Status: Enrolling
Updated:  4/2/2016
Clinical Research Facility
mi
from
Whittier, CA
HELOISE Study: A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer
Status: Enrolling
Updated: 4/2/2016
Clinical Research Facility
mi
from
Whittier, CA
Click here to add this to my saved trials
HELOISE Study: A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer
Status: Enrolling
Updated:  4/2/2016
Clinical Research Facility
mi
from
Whittier, CA
HELOISE Study: A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer
Status: Enrolling
Updated: 4/2/2016
Clinical Research Facility
mi
from
Whittier, CA
Click here to add this to my saved trials
HELOISE Study: A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer
Status: Enrolling
Updated:  4/2/2016
Clinical Research Facility
mi
from
Goshen, IN
HELOISE Study: A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer
Status: Enrolling
Updated: 4/2/2016
Clinical Research Facility
mi
from
Goshen, IN
Click here to add this to my saved trials
HELOISE Study: A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer
Status: Enrolling
Updated:  4/2/2016
Clinical Research Facility
mi
from
Wichita, KA
HELOISE Study: A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer
Status: Enrolling
Updated: 4/2/2016
Clinical Research Facility
mi
from
Wichita, KA
Click here to add this to my saved trials
HELOISE Study: A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer
Status: Enrolling
Updated:  4/2/2016
Clinical Research Facility
mi
from
New York, NY
HELOISE Study: A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer
Status: Enrolling
Updated: 4/2/2016
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
HELOISE Study: A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer
Status: Enrolling
Updated:  4/2/2016
Clinical Research Facility
mi
from
Portland, OR
HELOISE Study: A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer
Status: Enrolling
Updated: 4/2/2016
Clinical Research Facility
mi
from
Portland, OR
Click here to add this to my saved trials
HELOISE Study: A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer
Status: Enrolling
Updated:  4/2/2016
Clinical Research Facility
mi
from
Charleston, SC
HELOISE Study: A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer
Status: Enrolling
Updated: 4/2/2016
Clinical Research Facility
mi
from
Charleston, SC
Click here to add this to my saved trials
HELOISE Study: A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer
Status: Enrolling
Updated:  4/2/2016
mi
from
Port Macquarie,
HELOISE Study: A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer
Status: Enrolling
Updated: 4/2/2016
mi
from
Port Macquarie,
Click here to add this to my saved trials
A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer
A Randomized, Multicenter, Adaptive Phase II/III Study To Evaluate The Efficacy And Safety Of Trastuzumab Emtansine (T-DM1) Versus Taxane (Docetaxel Or Paclitaxel) In Patients With Previously Treated Locally Advanced Or Metastatic Her2-Positive Gastric Cancer, Including Adenocarcinoma Of The Gastroesophageal Junction
Status: Enrolling
Updated:  4/2/2016
Clinical Research Facility
mi
from
Bakersfield, CA
A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer
A Randomized, Multicenter, Adaptive Phase II/III Study To Evaluate The Efficacy And Safety Of Trastuzumab Emtansine (T-DM1) Versus Taxane (Docetaxel Or Paclitaxel) In Patients With Previously Treated Locally Advanced Or Metastatic Her2-Positive Gastric Cancer, Including Adenocarcinoma Of The Gastroesophageal Junction
Status: Enrolling
Updated: 4/2/2016
Clinical Research Facility
mi
from
Bakersfield, CA
Click here to add this to my saved trials
A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer
A Randomized, Multicenter, Adaptive Phase II/III Study To Evaluate The Efficacy And Safety Of Trastuzumab Emtansine (T-DM1) Versus Taxane (Docetaxel Or Paclitaxel) In Patients With Previously Treated Locally Advanced Or Metastatic Her2-Positive Gastric Cancer, Including Adenocarcinoma Of The Gastroesophageal Junction
Status: Enrolling
Updated:  4/2/2016
Clinical Research Facility
mi
from
Stanford, CA
A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer
A Randomized, Multicenter, Adaptive Phase II/III Study To Evaluate The Efficacy And Safety Of Trastuzumab Emtansine (T-DM1) Versus Taxane (Docetaxel Or Paclitaxel) In Patients With Previously Treated Locally Advanced Or Metastatic Her2-Positive Gastric Cancer, Including Adenocarcinoma Of The Gastroesophageal Junction
Status: Enrolling
Updated: 4/2/2016
Clinical Research Facility
mi
from
Stanford, CA
Click here to add this to my saved trials
A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer
A Randomized, Multicenter, Adaptive Phase II/III Study To Evaluate The Efficacy And Safety Of Trastuzumab Emtansine (T-DM1) Versus Taxane (Docetaxel Or Paclitaxel) In Patients With Previously Treated Locally Advanced Or Metastatic Her2-Positive Gastric Cancer, Including Adenocarcinoma Of The Gastroesophageal Junction
Status: Enrolling
Updated:  4/2/2016
Clinical Research Facility
mi
from
New Haven, CT
A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer
A Randomized, Multicenter, Adaptive Phase II/III Study To Evaluate The Efficacy And Safety Of Trastuzumab Emtansine (T-DM1) Versus Taxane (Docetaxel Or Paclitaxel) In Patients With Previously Treated Locally Advanced Or Metastatic Her2-Positive Gastric Cancer, Including Adenocarcinoma Of The Gastroesophageal Junction
Status: Enrolling
Updated: 4/2/2016
Clinical Research Facility
mi
from
New Haven, CT
Click here to add this to my saved trials
A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer
A Randomized, Multicenter, Adaptive Phase II/III Study To Evaluate The Efficacy And Safety Of Trastuzumab Emtansine (T-DM1) Versus Taxane (Docetaxel Or Paclitaxel) In Patients With Previously Treated Locally Advanced Or Metastatic Her2-Positive Gastric Cancer, Including Adenocarcinoma Of The Gastroesophageal Junction
Status: Enrolling
Updated:  4/2/2016
Clinical Research Facility
mi
from
Westwood, KA
A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer
A Randomized, Multicenter, Adaptive Phase II/III Study To Evaluate The Efficacy And Safety Of Trastuzumab Emtansine (T-DM1) Versus Taxane (Docetaxel Or Paclitaxel) In Patients With Previously Treated Locally Advanced Or Metastatic Her2-Positive Gastric Cancer, Including Adenocarcinoma Of The Gastroesophageal Junction
Status: Enrolling
Updated: 4/2/2016
Clinical Research Facility
mi
from
Westwood, KA
Click here to add this to my saved trials
A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer
A Randomized, Multicenter, Adaptive Phase II/III Study To Evaluate The Efficacy And Safety Of Trastuzumab Emtansine (T-DM1) Versus Taxane (Docetaxel Or Paclitaxel) In Patients With Previously Treated Locally Advanced Or Metastatic Her2-Positive Gastric Cancer, Including Adenocarcinoma Of The Gastroesophageal Junction
Status: Enrolling
Updated:  4/2/2016
Clinical Research Facility
mi
from
Louisville, KY
A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer
A Randomized, Multicenter, Adaptive Phase II/III Study To Evaluate The Efficacy And Safety Of Trastuzumab Emtansine (T-DM1) Versus Taxane (Docetaxel Or Paclitaxel) In Patients With Previously Treated Locally Advanced Or Metastatic Her2-Positive Gastric Cancer, Including Adenocarcinoma Of The Gastroesophageal Junction
Status: Enrolling
Updated: 4/2/2016
Clinical Research Facility
mi
from
Louisville, KY
Click here to add this to my saved trials
A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer
A Randomized, Multicenter, Adaptive Phase II/III Study To Evaluate The Efficacy And Safety Of Trastuzumab Emtansine (T-DM1) Versus Taxane (Docetaxel Or Paclitaxel) In Patients With Previously Treated Locally Advanced Or Metastatic Her2-Positive Gastric Cancer, Including Adenocarcinoma Of The Gastroesophageal Junction
Status: Enrolling
Updated:  4/2/2016
Clinical Research Facility
mi
from
Boston, MA
A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer
A Randomized, Multicenter, Adaptive Phase II/III Study To Evaluate The Efficacy And Safety Of Trastuzumab Emtansine (T-DM1) Versus Taxane (Docetaxel Or Paclitaxel) In Patients With Previously Treated Locally Advanced Or Metastatic Her2-Positive Gastric Cancer, Including Adenocarcinoma Of The Gastroesophageal Junction
Status: Enrolling
Updated: 4/2/2016
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer
A Randomized, Multicenter, Adaptive Phase II/III Study To Evaluate The Efficacy And Safety Of Trastuzumab Emtansine (T-DM1) Versus Taxane (Docetaxel Or Paclitaxel) In Patients With Previously Treated Locally Advanced Or Metastatic Her2-Positive Gastric Cancer, Including Adenocarcinoma Of The Gastroesophageal Junction
Status: Enrolling
Updated:  4/2/2016
Clinical Research Facility
mi
from
Boston, MA
A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer
A Randomized, Multicenter, Adaptive Phase II/III Study To Evaluate The Efficacy And Safety Of Trastuzumab Emtansine (T-DM1) Versus Taxane (Docetaxel Or Paclitaxel) In Patients With Previously Treated Locally Advanced Or Metastatic Her2-Positive Gastric Cancer, Including Adenocarcinoma Of The Gastroesophageal Junction
Status: Enrolling
Updated: 4/2/2016
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer
A Randomized, Multicenter, Adaptive Phase II/III Study To Evaluate The Efficacy And Safety Of Trastuzumab Emtansine (T-DM1) Versus Taxane (Docetaxel Or Paclitaxel) In Patients With Previously Treated Locally Advanced Or Metastatic Her2-Positive Gastric Cancer, Including Adenocarcinoma Of The Gastroesophageal Junction
Status: Enrolling
Updated:  4/2/2016
Clinical Research Facility
mi
from
New York, NY
A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer
A Randomized, Multicenter, Adaptive Phase II/III Study To Evaluate The Efficacy And Safety Of Trastuzumab Emtansine (T-DM1) Versus Taxane (Docetaxel Or Paclitaxel) In Patients With Previously Treated Locally Advanced Or Metastatic Her2-Positive Gastric Cancer, Including Adenocarcinoma Of The Gastroesophageal Junction
Status: Enrolling
Updated: 4/2/2016
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer
A Randomized, Multicenter, Adaptive Phase II/III Study To Evaluate The Efficacy And Safety Of Trastuzumab Emtansine (T-DM1) Versus Taxane (Docetaxel Or Paclitaxel) In Patients With Previously Treated Locally Advanced Or Metastatic Her2-Positive Gastric Cancer, Including Adenocarcinoma Of The Gastroesophageal Junction
Status: Enrolling
Updated:  4/2/2016
Clinical Research Facility
mi
from
Nashville, TN
A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer
A Randomized, Multicenter, Adaptive Phase II/III Study To Evaluate The Efficacy And Safety Of Trastuzumab Emtansine (T-DM1) Versus Taxane (Docetaxel Or Paclitaxel) In Patients With Previously Treated Locally Advanced Or Metastatic Her2-Positive Gastric Cancer, Including Adenocarcinoma Of The Gastroesophageal Junction
Status: Enrolling
Updated: 4/2/2016
Clinical Research Facility
mi
from
Nashville, TN
Click here to add this to my saved trials
A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer
A Randomized, Multicenter, Adaptive Phase II/III Study To Evaluate The Efficacy And Safety Of Trastuzumab Emtansine (T-DM1) Versus Taxane (Docetaxel Or Paclitaxel) In Patients With Previously Treated Locally Advanced Or Metastatic Her2-Positive Gastric Cancer, Including Adenocarcinoma Of The Gastroesophageal Junction
Status: Enrolling
Updated:  4/2/2016
Clinical Research Facility
mi
from
Houston, TX
A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer
A Randomized, Multicenter, Adaptive Phase II/III Study To Evaluate The Efficacy And Safety Of Trastuzumab Emtansine (T-DM1) Versus Taxane (Docetaxel Or Paclitaxel) In Patients With Previously Treated Locally Advanced Or Metastatic Her2-Positive Gastric Cancer, Including Adenocarcinoma Of The Gastroesophageal Junction
Status: Enrolling
Updated: 4/2/2016
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer
A Randomized, Multicenter, Adaptive Phase II/III Study To Evaluate The Efficacy And Safety Of Trastuzumab Emtansine (T-DM1) Versus Taxane (Docetaxel Or Paclitaxel) In Patients With Previously Treated Locally Advanced Or Metastatic Her2-Positive Gastric Cancer, Including Adenocarcinoma Of The Gastroesophageal Junction
Status: Enrolling
Updated:  4/2/2016
mi
from
Buenos Aires,
A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer
A Randomized, Multicenter, Adaptive Phase II/III Study To Evaluate The Efficacy And Safety Of Trastuzumab Emtansine (T-DM1) Versus Taxane (Docetaxel Or Paclitaxel) In Patients With Previously Treated Locally Advanced Or Metastatic Her2-Positive Gastric Cancer, Including Adenocarcinoma Of The Gastroesophageal Junction
Status: Enrolling
Updated: 4/2/2016
mi
from
Buenos Aires,
Click here to add this to my saved trials
A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)
Screening Protocol to Detect BRAF V600 Mutation-Positive Patients for Enrollment Into Clinical Research Studies of Vemurafenib
Status: Enrolling
Updated:  4/2/2016
Clinical Research Facility
mi
from
Dallas, TX
A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)
Screening Protocol to Detect BRAF V600 Mutation-Positive Patients for Enrollment Into Clinical Research Studies of Vemurafenib
Status: Enrolling
Updated: 4/2/2016
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)
Screening Protocol to Detect BRAF V600 Mutation-Positive Patients for Enrollment Into Clinical Research Studies of Vemurafenib
Status: Enrolling
Updated:  4/2/2016
Clinical Research Facility
mi
from
Sedona, AZ
A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)
Screening Protocol to Detect BRAF V600 Mutation-Positive Patients for Enrollment Into Clinical Research Studies of Vemurafenib
Status: Enrolling
Updated: 4/2/2016
Clinical Research Facility
mi
from
Sedona, AZ
Click here to add this to my saved trials
A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)
Screening Protocol to Detect BRAF V600 Mutation-Positive Patients for Enrollment Into Clinical Research Studies of Vemurafenib
Status: Enrolling
Updated:  4/2/2016
Clinical Research Facility
mi
from
Tucson, AZ
A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)
Screening Protocol to Detect BRAF V600 Mutation-Positive Patients for Enrollment Into Clinical Research Studies of Vemurafenib
Status: Enrolling
Updated: 4/2/2016
Clinical Research Facility
mi
from
Tucson, AZ
Click here to add this to my saved trials
A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)
Screening Protocol to Detect BRAF V600 Mutation-Positive Patients for Enrollment Into Clinical Research Studies of Vemurafenib
Status: Enrolling
Updated:  4/2/2016
Clinical Research Facility
mi
from
Burbank, CA
A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)
Screening Protocol to Detect BRAF V600 Mutation-Positive Patients for Enrollment Into Clinical Research Studies of Vemurafenib
Status: Enrolling
Updated: 4/2/2016
Clinical Research Facility
mi
from
Burbank, CA
Click here to add this to my saved trials
A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)
Screening Protocol to Detect BRAF V600 Mutation-Positive Patients for Enrollment Into Clinical Research Studies of Vemurafenib
Status: Enrolling
Updated:  4/2/2016
Clinical Research Facility
mi
from
Rancho Cucamonga, CA
A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)
Screening Protocol to Detect BRAF V600 Mutation-Positive Patients for Enrollment Into Clinical Research Studies of Vemurafenib
Status: Enrolling
Updated: 4/2/2016
Clinical Research Facility
mi
from
Rancho Cucamonga, CA
Click here to add this to my saved trials
A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)
Screening Protocol to Detect BRAF V600 Mutation-Positive Patients for Enrollment Into Clinical Research Studies of Vemurafenib
Status: Enrolling
Updated:  4/2/2016
Clinical Research Facility
mi
from
Denver, CO
A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)
Screening Protocol to Detect BRAF V600 Mutation-Positive Patients for Enrollment Into Clinical Research Studies of Vemurafenib
Status: Enrolling
Updated: 4/2/2016
Clinical Research Facility
mi
from
Denver, CO
Click here to add this to my saved trials
A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)
Screening Protocol to Detect BRAF V600 Mutation-Positive Patients for Enrollment Into Clinical Research Studies of Vemurafenib
Status: Enrolling
Updated:  4/2/2016
Clinical Research Facility
mi
from
Ocala, FL
A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)
Screening Protocol to Detect BRAF V600 Mutation-Positive Patients for Enrollment Into Clinical Research Studies of Vemurafenib
Status: Enrolling
Updated: 4/2/2016
Clinical Research Facility
mi
from
Ocala, FL
Click here to add this to my saved trials
A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)
Screening Protocol to Detect BRAF V600 Mutation-Positive Patients for Enrollment Into Clinical Research Studies of Vemurafenib
Status: Enrolling
Updated:  4/2/2016
Clinical Research Facility
mi
from
Woodbury, MN
A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)
Screening Protocol to Detect BRAF V600 Mutation-Positive Patients for Enrollment Into Clinical Research Studies of Vemurafenib
Status: Enrolling
Updated: 4/2/2016
Clinical Research Facility
mi
from
Woodbury, MN
Click here to add this to my saved trials
A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)
Screening Protocol to Detect BRAF V600 Mutation-Positive Patients for Enrollment Into Clinical Research Studies of Vemurafenib
Status: Enrolling
Updated:  4/2/2016
Clinical Research Facility
mi
from
Columbia, MO
A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)
Screening Protocol to Detect BRAF V600 Mutation-Positive Patients for Enrollment Into Clinical Research Studies of Vemurafenib
Status: Enrolling
Updated: 4/2/2016
Clinical Research Facility
mi
from
Columbia, MO
Click here to add this to my saved trials
A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)
Screening Protocol to Detect BRAF V600 Mutation-Positive Patients for Enrollment Into Clinical Research Studies of Vemurafenib
Status: Enrolling
Updated:  4/2/2016
Clinical Research Facility
mi
from
Las Vegas, NV
A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)
Screening Protocol to Detect BRAF V600 Mutation-Positive Patients for Enrollment Into Clinical Research Studies of Vemurafenib
Status: Enrolling
Updated: 4/2/2016
Clinical Research Facility
mi
from
Las Vegas, NV
Click here to add this to my saved trials
A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)
Screening Protocol to Detect BRAF V600 Mutation-Positive Patients for Enrollment Into Clinical Research Studies of Vemurafenib
Status: Enrolling
Updated:  4/2/2016
Clinical Research Facility
mi
from
Nashville, TN
A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)
Screening Protocol to Detect BRAF V600 Mutation-Positive Patients for Enrollment Into Clinical Research Studies of Vemurafenib
Status: Enrolling
Updated: 4/2/2016
Clinical Research Facility
mi
from
Nashville, TN
Click here to add this to my saved trials
A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)
Screening Protocol to Detect BRAF V600 Mutation-Positive Patients for Enrollment Into Clinical Research Studies of Vemurafenib
Status: Enrolling
Updated:  4/2/2016
Clinical Research Facility
mi
from
Amarillo, TX
A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)
Screening Protocol to Detect BRAF V600 Mutation-Positive Patients for Enrollment Into Clinical Research Studies of Vemurafenib
Status: Enrolling
Updated: 4/2/2016
Clinical Research Facility
mi
from
Amarillo, TX
Click here to add this to my saved trials
A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)
Screening Protocol to Detect BRAF V600 Mutation-Positive Patients for Enrollment Into Clinical Research Studies of Vemurafenib
Status: Enrolling
Updated:  4/2/2016
Clinical Research Facility
mi
from
Austin, TX
A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)
Screening Protocol to Detect BRAF V600 Mutation-Positive Patients for Enrollment Into Clinical Research Studies of Vemurafenib
Status: Enrolling
Updated: 4/2/2016
Clinical Research Facility
mi
from
Austin, TX
Click here to add this to my saved trials
A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)
Screening Protocol to Detect BRAF V600 Mutation-Positive Patients for Enrollment Into Clinical Research Studies of Vemurafenib
Status: Enrolling
Updated:  4/2/2016
Clinical Research Facility
mi
from
Denton, TX
A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)
Screening Protocol to Detect BRAF V600 Mutation-Positive Patients for Enrollment Into Clinical Research Studies of Vemurafenib
Status: Enrolling
Updated: 4/2/2016
Clinical Research Facility
mi
from
Denton, TX
Click here to add this to my saved trials
A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)
Screening Protocol to Detect BRAF V600 Mutation-Positive Patients for Enrollment Into Clinical Research Studies of Vemurafenib
Status: Enrolling
Updated:  4/2/2016
Clinical Research Facility
mi
from
McAllen, TX
A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)
Screening Protocol to Detect BRAF V600 Mutation-Positive Patients for Enrollment Into Clinical Research Studies of Vemurafenib
Status: Enrolling
Updated: 4/2/2016
Clinical Research Facility
mi
from
McAllen, TX
Click here to add this to my saved trials
A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)
Screening Protocol to Detect BRAF V600 Mutation-Positive Patients for Enrollment Into Clinical Research Studies of Vemurafenib
Status: Enrolling
Updated:  4/2/2016
Clinical Research Facility
mi
from
Tyler, TX
A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)
Screening Protocol to Detect BRAF V600 Mutation-Positive Patients for Enrollment Into Clinical Research Studies of Vemurafenib
Status: Enrolling
Updated: 4/2/2016
Clinical Research Facility
mi
from
Tyler, TX
Click here to add this to my saved trials
A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)
Screening Protocol to Detect BRAF V600 Mutation-Positive Patients for Enrollment Into Clinical Research Studies of Vemurafenib
Status: Enrolling
Updated:  4/2/2016
Clinical Research Facility
mi
from
Spokane, WA
A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)
Screening Protocol to Detect BRAF V600 Mutation-Positive Patients for Enrollment Into Clinical Research Studies of Vemurafenib
Status: Enrolling
Updated: 4/2/2016
Clinical Research Facility
mi
from
Spokane, WA
Click here to add this to my saved trials
A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)
Screening Protocol to Detect BRAF V600 Mutation-Positive Patients for Enrollment Into Clinical Research Studies of Vemurafenib
Status: Enrolling
Updated:  4/2/2016
Clinical Research Facility
mi
from
Yakima, WA
A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)
Screening Protocol to Detect BRAF V600 Mutation-Positive Patients for Enrollment Into Clinical Research Studies of Vemurafenib
Status: Enrolling
Updated: 4/2/2016
Clinical Research Facility
mi
from
Yakima, WA
Click here to add this to my saved trials
IMRT Tomotherapy for Esophagus Cancer
IMRT Tomotherapy for Esophagus Cancer: A Phase I Feasibility Study in Non-Operative Patients
Status: Enrolling
Updated:  4/3/2016
Washington University School of Medicine
mi
from
St. Louis, MO
IMRT Tomotherapy for Esophagus Cancer
IMRT Tomotherapy for Esophagus Cancer: A Phase I Feasibility Study in Non-Operative Patients
Status: Enrolling
Updated: 4/3/2016
Washington University School of Medicine
mi
from
St. Louis, MO
Click here to add this to my saved trials
Study of LY2784544 Testing Alternative Dosing in Participants With Myeloproliferative Neoplasms
A Phase 1 Study of LY2784544 Testing Alternative Dosing Regimens in Patients With Myeloproliferative Neoplasms
Status: Enrolling
Updated:  4/4/2016
Clinical Research Facility
mi
from
Birmingham, AL
Study of LY2784544 Testing Alternative Dosing in Participants With Myeloproliferative Neoplasms
A Phase 1 Study of LY2784544 Testing Alternative Dosing Regimens in Patients With Myeloproliferative Neoplasms
Status: Enrolling
Updated: 4/4/2016
Clinical Research Facility
mi
from
Birmingham, AL
Click here to add this to my saved trials
Study of LY2784544 Testing Alternative Dosing in Participants With Myeloproliferative Neoplasms
A Phase 1 Study of LY2784544 Testing Alternative Dosing Regimens in Patients With Myeloproliferative Neoplasms
Status: Enrolling
Updated:  4/4/2016
Clinical Research Facility
mi
from
Scottsdale, AZ
Study of LY2784544 Testing Alternative Dosing in Participants With Myeloproliferative Neoplasms
A Phase 1 Study of LY2784544 Testing Alternative Dosing Regimens in Patients With Myeloproliferative Neoplasms
Status: Enrolling
Updated: 4/4/2016
Clinical Research Facility
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Study of LY2784544 Testing Alternative Dosing in Participants With Myeloproliferative Neoplasms
A Phase 1 Study of LY2784544 Testing Alternative Dosing Regimens in Patients With Myeloproliferative Neoplasms
Status: Enrolling
Updated:  4/4/2016
Clinical Research Facility
mi
from
Fayetteville, AR
Study of LY2784544 Testing Alternative Dosing in Participants With Myeloproliferative Neoplasms
A Phase 1 Study of LY2784544 Testing Alternative Dosing Regimens in Patients With Myeloproliferative Neoplasms
Status: Enrolling
Updated: 4/4/2016
Clinical Research Facility
mi
from
Fayetteville, AR
Click here to add this to my saved trials
Study of LY2784544 Testing Alternative Dosing in Participants With Myeloproliferative Neoplasms
A Phase 1 Study of LY2784544 Testing Alternative Dosing Regimens in Patients With Myeloproliferative Neoplasms
Status: Enrolling
Updated:  4/4/2016
Clinical Research Facility
mi
from
Washington,
Study of LY2784544 Testing Alternative Dosing in Participants With Myeloproliferative Neoplasms
A Phase 1 Study of LY2784544 Testing Alternative Dosing Regimens in Patients With Myeloproliferative Neoplasms
Status: Enrolling
Updated: 4/4/2016
Clinical Research Facility
mi
from
Washington,
Click here to add this to my saved trials
Study of LY2784544 Testing Alternative Dosing in Participants With Myeloproliferative Neoplasms
A Phase 1 Study of LY2784544 Testing Alternative Dosing Regimens in Patients With Myeloproliferative Neoplasms
Status: Enrolling
Updated:  4/4/2016
Clinical Research Facility
mi
from
Jacksonville, FL
Study of LY2784544 Testing Alternative Dosing in Participants With Myeloproliferative Neoplasms
A Phase 1 Study of LY2784544 Testing Alternative Dosing Regimens in Patients With Myeloproliferative Neoplasms
Status: Enrolling
Updated: 4/4/2016
Clinical Research Facility
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Study of LY2784544 Testing Alternative Dosing in Participants With Myeloproliferative Neoplasms
A Phase 1 Study of LY2784544 Testing Alternative Dosing Regimens in Patients With Myeloproliferative Neoplasms
Status: Enrolling
Updated:  4/4/2016
Clinical Research Facility
mi
from
Honolulu, HI
Study of LY2784544 Testing Alternative Dosing in Participants With Myeloproliferative Neoplasms
A Phase 1 Study of LY2784544 Testing Alternative Dosing Regimens in Patients With Myeloproliferative Neoplasms
Status: Enrolling
Updated: 4/4/2016
Clinical Research Facility
mi
from
Honolulu, HI
Click here to add this to my saved trials